|
Other ureteric obstruction
|
0.200 |
Biomarker
|
phenotype |
RGD |
Reactive oxygen species modulator 1 regulates oxidative stress and induces renal and pulmonary fibrosis in a unilateral ureteral obstruction rat model and in HK‑2 cells.
|
28791399 |
2017 |
|
Protein C measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Genome-wide association study identifies novel loci for plasma levels of protein C: the ARIC study.
|
20802025 |
2010 |
|
Protein C antigen measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Genome-wide association study identifies novel loci for plasma levels of protein C: the ARIC study.
|
20802025 |
2010 |
|
Malignant Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Although increased ROMO1 expression has been associated with poor clinical outcomes in several human malignancies, the clinical implication of this protein in a radiotherapy setting has never been explored.
|
31632076 |
2019 |
|
Malignant Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Reactive oxygen species modulator-1 (Romo1) is a protein that modulates levels of reactive oxygen species (ROS) and has been reported to affect cancer cell invasion and proliferation via persistent inflammation.
|
30087567 |
2018 |
|
Malignant Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Cancer invasiveness appeared to be a key reason for the poor survival related to highly expressed Romo1.
|
28472059 |
2017 |
|
Malignant Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Romo1 is overexpressed in most cancer cell lines and related to invasiveness and chemoresistance in vitro.
|
25468147 |
2015 |
|
Malignant Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Increased expression of reactive oxygen species modulator 1 protein-triggered reactive oxygen species production was reported in the mitochondria of various cancer cell lines.
|
25374412 |
2015 |
|
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
This study has focused on reactive oxygen species Modulator-1 (ROMO1), an oncomarker and mitochondrial membrane protein, which is known to be associated with cancer growth and in the modulation of RedOx states in some cancer models.
|
25687884 |
2015 |
|
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Therefore, our data demonstrate that Romo1 upregulation is a common event in human GBMs and contributes to the malignant tumor progression, suggesting that Romo1 could be a new therapeutic target for human GBM.
|
25193023 |
2015 |
|
Malignant Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
This suggests that the increased Romo1 expression during cancer progression may cause persistent oxidative stress to tumor cells, which can increase their malignancy.
|
16842742 |
2006 |
|
Primary malignant neoplasm
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Reactive oxygen species modulator-1 (Romo1) is a protein that modulates levels of reactive oxygen species (ROS) and has been reported to affect cancer cell invasion and proliferation via persistent inflammation.
|
30087567 |
2018 |
|
Primary malignant neoplasm
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Cancer invasiveness appeared to be a key reason for the poor survival related to highly expressed Romo1.
|
28472059 |
2017 |
|
Primary malignant neoplasm
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Romo1 is overexpressed in most cancer cell lines and related to invasiveness and chemoresistance in vitro.
|
25468147 |
2015 |
|
Primary malignant neoplasm
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Increased expression of reactive oxygen species modulator 1 protein-triggered reactive oxygen species production was reported in the mitochondria of various cancer cell lines.
|
25374412 |
2015 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
This study has focused on reactive oxygen species Modulator-1 (ROMO1), an oncomarker and mitochondrial membrane protein, which is known to be associated with cancer growth and in the modulation of RedOx states in some cancer models.
|
25687884 |
2015 |
|
Primary malignant neoplasm
|
0.060 |
AlteredExpression
|
group |
BEFREE |
This suggests that the increased Romo1 expression during cancer progression may cause persistent oxidative stress to tumor cells, which can increase their malignancy.
|
16842742 |
2006 |
|
Non-Small Cell Lung Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
The combined detection of ROMO1 + ADA in pleural effusion is an effective biomarker for identifying MPE caused by NSCLC.
|
31709646 |
2020 |
|
Non-Small Cell Lung Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
ROMO1 protein expression was evaluated immunohistochemically using histologic score (H-score) in 49 tumor tissues from stage III non-small cell lung cancer (NSCLC) patients treated with definitive radiotherapy.
|
31632076 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Several studies have demonstrated the clinical application of Romo1 as a prognostic marker in non-small cell lung cancer (NSCLC); however, there have been no studies investigating the mechanism by which Romo1 adversely affects the prognosis of these patients.
|
30087567 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
We evaluated the association of Romo1 expression with clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
|
27188201 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
We investigated the association between Romo1 expression and the clinical outcomes of non-small cell lung cancer (NSCLC) patients who underwent surgical resection.
|
25468147 |
2015 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Romo1 expression in tumor tissue was examined by immunohistochemistry and evaluated by histological score.
|
27188201 |
2017 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Romo1 overexpression in tumor tissue was significantly associated with survival in curatively resected colorectal cancer patients, suggesting Romo1 expression as a potential adverse prognostic marker.
|
28472059 |
2017 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Multivariate analyses showed that high Romo1 expression in tumor tissues was significantly associated with short disease-free survival (hazard ratio [HR]=3.16, 95% confidence interval [CI]: 1.21-8.22), and with short overall survival (HR=3.22, 95% CI: 1.02-10.21).
|
25468147 |
2015 |